Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896487441> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2896487441 endingPage "e233" @default.
- W2896487441 startingPage "e232" @default.
- W2896487441 abstract "The primary treatment for spinal ependymoma is surgical resection. However, some cases cannot achieve complete resection because of either neurological compromise or disseminated feature. In these cases, radiotherapy (RT) is generally recommended, however, the role of RT has not been fully elucidated. This study evaluated the clinical outcome of RT on spinal ependymoma with the adverse feature, such as incomplete resection or disseminated disease. Between 1991 and 2016, 25 patients with spinal cord ependymoma treated with radiotherapy (RT) in a single institution were retrospectively reviewed. All except one patient with anaplastic ependymoma had gross disease in spinal MRI before RT. Eighteen (64%) underwent subtotal resection, while 6 (24%) did not undergo surgical resection. Six (24%) had multiple disseminated diseases. World Health Organization grade was I in 12 patients, II in 12 patients, and III in 1 patient. Nineteen (76%), 5 (20%), and 1 (4%) patients received RT to the localized disease, craniospinal area, and whole spinal cord with posterior cranial fossa, respectively. Median RT dose was 50.4 Gy (range, 44.0–59.4). With a median follow-up period of 49 months (range, 9–321 months), disease progression was observed in 4 patients, of whom 2 had clear cell ependymoma (grade II), and 2 had classic ependymoma (grade II). There was no failure or death in 12 patients with grade I ependymoma. Of 6 patients with disseminated disease, 3 had not experienced disease progression with follow-up of 111 months, 45 months, and 49 months, respectively. Of 18 patients with localized disease, 16 had not experienced disease progression until the last follow-up. In all patients, the 2- and 5-year progression-free survival rates were 91.7% and 79.6%, respectively, and overall survival rates were 95.7% and 83.7% respectively. Of patients with grade I ependymoma, the 2- and 5-year overall survival rates were 100%, while those were 91.7% and 69.4%, respectively, in patients with grade II or III ependymoma. Twelve (48%) showed improved neurologic function after RT. Late toxicity (hypopituitarism) occurred in 1 patient who received craniospinal irradiation. Favorable PFS and OS could be achieved with RT in spinal ependymoma with adverse features. RT appears to be an effective treatment option for spinal ependymoma in cases when complete tumor removal cannot be achieved." @default.
- W2896487441 created "2018-10-26" @default.
- W2896487441 creator A5011135188 @default.
- W2896487441 creator A5051305073 @default.
- W2896487441 creator A5071552674 @default.
- W2896487441 creator A5084782886 @default.
- W2896487441 date "2018-11-01" @default.
- W2896487441 modified "2023-10-01" @default.
- W2896487441 title "The Clinical Results of Radiation Therapy for Spinal Cord Ependymoma with Adverse Prognostic Features: A Single-Institution Experience" @default.
- W2896487441 doi "https://doi.org/10.1016/j.ijrobp.2018.07.788" @default.
- W2896487441 hasPublicationYear "2018" @default.
- W2896487441 type Work @default.
- W2896487441 sameAs 2896487441 @default.
- W2896487441 citedByCount "0" @default.
- W2896487441 crossrefType "journal-article" @default.
- W2896487441 hasAuthorship W2896487441A5011135188 @default.
- W2896487441 hasAuthorship W2896487441A5051305073 @default.
- W2896487441 hasAuthorship W2896487441A5071552674 @default.
- W2896487441 hasAuthorship W2896487441A5084782886 @default.
- W2896487441 hasConcept C118552586 @default.
- W2896487441 hasConcept C126838900 @default.
- W2896487441 hasConcept C141071460 @default.
- W2896487441 hasConcept C2780775167 @default.
- W2896487441 hasConcept C2781432949 @default.
- W2896487441 hasConcept C509974204 @default.
- W2896487441 hasConcept C71924100 @default.
- W2896487441 hasConceptScore W2896487441C118552586 @default.
- W2896487441 hasConceptScore W2896487441C126838900 @default.
- W2896487441 hasConceptScore W2896487441C141071460 @default.
- W2896487441 hasConceptScore W2896487441C2780775167 @default.
- W2896487441 hasConceptScore W2896487441C2781432949 @default.
- W2896487441 hasConceptScore W2896487441C509974204 @default.
- W2896487441 hasConceptScore W2896487441C71924100 @default.
- W2896487441 hasIssue "3" @default.
- W2896487441 hasLocation W28964874411 @default.
- W2896487441 hasOpenAccess W2896487441 @default.
- W2896487441 hasPrimaryLocation W28964874411 @default.
- W2896487441 hasRelatedWork W1991470708 @default.
- W2896487441 hasRelatedWork W2002120878 @default.
- W2896487441 hasRelatedWork W2003938723 @default.
- W2896487441 hasRelatedWork W2047967234 @default.
- W2896487441 hasRelatedWork W2118496982 @default.
- W2896487441 hasRelatedWork W2439875401 @default.
- W2896487441 hasRelatedWork W2463539170 @default.
- W2896487441 hasRelatedWork W2528960518 @default.
- W2896487441 hasRelatedWork W3102301162 @default.
- W2896487441 hasRelatedWork W2525756941 @default.
- W2896487441 hasVolume "102" @default.
- W2896487441 isParatext "false" @default.
- W2896487441 isRetracted "false" @default.
- W2896487441 magId "2896487441" @default.
- W2896487441 workType "article" @default.